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Structural mechanism for signal transduction in
RXR nuclear receptor heterodimers
Douglas J. Kojetin1, Edna Matta-Camacho1, Travis S. Hughes1, Sathish Srinivasan2, Jerome C. Nwachukwu2,
Valerie Cavett2, Jason Nowak2, Michael J. Chalmers1, David P. Marciano1, Theodore M. Kamenecka1,
Andrew I. Shulman3,w, Mark Rance4, Patrick R. Grifﬁn1, John B. Bruning5 & Kendall W. Nettles2
A subset of nuclear receptors (NRs) function as obligate heterodimers with retinoid
X receptor (RXR), allowing integration of ligand-dependent signals across the dimer interface
via an unknown structural mechanism. Using nuclear magnetic resonance (NMR) spectro-
scopy, x-ray crystallography and hydrogen/deuterium exchange (HDX) mass spectrometry,
here we show an allosteric mechanism through which RXR co-operates with a permissive
dimer partner, peroxisome proliferator-activated receptor (PPAR)-g, while rendered generally
unresponsive by a non-permissive dimer partner, thyroid hormone (TR) receptor. Amino acid
residues that mediate this allosteric mechanism comprise an evolutionarily conserved net-
work discovered by statistical coupling analysis (SCA). This SCA network acts as a signalling
rheostat to integrate signals between dimer partners, ligands and coregulator-binding sites,
thereby affecting signal transmission in RXR heterodimers. These ﬁndings deﬁne rules guiding
how NRs integrate two ligand-dependent signalling pathways into RXR heterodimer-speciﬁc
responses.
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T
he nuclear receptor (NR) superfamily of transcription
factors are broadly implicated in metazoan physiology,
and modulate gene expression in response to steroids,
lipids, bile acids and other small lipophilic molecules or
synthetic ligands1. NRs harbour a C-terminal ligand-binding
and transactivation domain (LBD), a central DNA-binding
domain and a variable N-terminal disordered transactivation
domain. These receptors transduce signals from ligand binding in
the LBD to regulate gene expression by recruiting co-regulator
proteins that modify chromatin and the associated transcriptional
complex2.
The physical mechanisms governing allosteric signalling
between NR ligands and coregulator-binding sites remain poorly
understood. Allosteric control of NR function is modulated by a
number of factors, including cell type-speciﬁc co-regulators3,
post-translational modiﬁcations4,5, DNA recognition elements6–8
and NR heterodimer partners9–11. Understanding the complex
allosteric signalling of NRs requires ﬁrst dissecting the
signalling mechanisms within individual domains and binding
sites, which will facilitate understanding the more difﬁcult
questions related to inter-domain communication12. Structural
studies have revealed mechanisms that direct communication
between ligand and coregulator-binding sites within a
single LBD13,14. The fully active LBD conformer is well-
characterized15–17 and its conformation is conserved within the
context of the full-length receptor18. In its agonist-stabilized
conformation, the C-terminal helix, helix 12 forms one side,
while helices 3–5 form the other sides of a co-regulator-binding
site called the Activation Function-2 (AF-2) surface. Some NR
antagonists, such as tamoxifen or RU486, contain a pendent side
group that physically relocates helix 12 out of the active
conformation thus blocking co-activator recruitment15,19,20.
More recently, we identiﬁed a ﬁne-tuning mechanism for
indirectly modulating helix 12 conformation, allowing NRs to
direct a graded range of signalling outputs from partial to full
agonist21–24. We have also deﬁned a structural mechanism
whereby graded agonists and non-agonists do not fully stabilize
the conformational dynamics of the AF-2 surface4,25–27.
However, it is poorly understood how ligand binding to one
LBD controls co-regulator recruitment to its dimer partner within
a NR heterodimer complex.
A subset of NRs functions as heterodimers with retinoid
X receptor (RXR), and thus provides a mechanism to integrate
two distinct ligand signalling pathways28. In some contexts, RXR
heterodimers can act as two independent signalling moieties29.
However, allosteric phenomena between RXR and partner are not
well-understood. First, some heterodimer partners, such as the
peroxisome proliferator-activated receptor-g (PPARg), farnesoid
X receptor and liver X receptor (LXR), are ‘permissive’ for RXR
activity, where the heterodimer is strongly activated by ligands for
either partner in the dimer30,31. However, the integration of
signals varies with both receptor and ligand combinations, which
can produce either additive or synergistic effects32,33. Second,
RXR heterodimers that contain retinoic acid receptor (RAR),
vitamin D receptor (VDR) or thyroid hormone receptor (TR), are
‘non-permissive’ for RXR as they generally do not respond to
RXR ligands34, or do so only in certain contexts in the presence of
the partner ligand35,36. The structural mechanisms that generate
this spectrum of signalling outcomes are unknown.
Here we present comprehensive structural analyses of a
‘permissive’ (PPARg/RXRa) and ‘non-permissive’ (TR/RXR)
heterodimeric complex, which deﬁnes how a non-permissive
dimer partner allosterically silences RXR. Solution nuclear
magnetic resonance (NMR) spectroscopy reveals a mechanism
by which the liganded state of TR, but not PPARg, uniquely
affects the conformational dynamics of RXR. A crystal structure
of the TR/RXR heterodimer deﬁnes a structural mechanism
for this silencing, which occurs through a sequence of
conformational relays between the helix 11 pairs that constitute
most of the dimer interface, transferred to a rotation of helix 5
in the core of the RXR LBD, leading to disruption of the adjacent
co-regulator- and ligand-binding sites. This allosteric signalling
pathway is further conﬁrmed by NMR and hydrogen/deuterium
exchange (HDX) mass spectrometry. Notably, analysis of
other NR dimers reveals that these structural changes are
part of an evolutionarily conserved energetic network, deﬁned
by a statistical coupling analysis (SCA) method10, where
helix 5 functions more generally as a signalling rheostat that
integrates signals with the dimer interface, ligand and
coregulator-binding sites.
Results
Conformational dynamics control RXR permissiveness. The
RXR agonist, 9-cis-retinoic acid (9cRA), stimulates transactiva-
tion of PPARg/RXRa (Fig. 1a), verifying PPARg as a permissive
RXRa partner. However, 9cRA and another RXR agonist,
LG100268 (LG268), have no effect on TRb/RXRa (Fig. 1b) and
VDR/RXRa (Supplementary Fig. 1), establishing TRb and VDR
as non-permissive RXR partners. To gain insight into the struc-
tural basis for this heterodimer-speciﬁc signalling, we performed
solution NMR on isotopically labelled RXRa LBD alone as a
homodimer, and in complex with unlabelled PPARg LBD or TRb
LBD as heterodimers. This analysis enabled us to speciﬁcally
observe conformational effects in RXRa that result from ligand
binding to its heterodimer partner.
NMR resonances corresponding to residues within the
apo-RXRa ligand-binding pocket and AF-2 surface are missing
or have broad linewidths. These regions exist as a dynamic
ensemble of conformations, exchanging between two or more
conformations in a molten globule-like state on the ms–ms
timescale37–39. Binding of 9cRA to the RXRa homodimer
stabilizes the ligand-binding pocket and AF-2 surface37
(Fig. 1b,c), resulting in the appearance and sharpening of NMR
resonances relative to apo-RXRa. Thus, the NMR-observed
structural mechanism by which an agonist activates RXRa
occurs by stabilizing an active conformation. That is, agonist
binding quenches the ms–ms conformational dynamics of the apo-
RXRa ligand-binding pocket and surrounding regions, including
the AF-2 surface. This mechanism is also supported by HDX mass
spectrometry studies, which demonstrate stabilization of the RXRa
ligand-binding pocket and AF-2 surface on ligand binding40–42.
This conformational activation phenotype, whereby the dynamics
of the apo-NR LBD is affected (stabilized) by agonist binding,
has been observed for PPARg25,26,39, VDR43,44, constitutive
androstane receptorc45 and other receptors, indicating this may
be a general feature for ligand activation of NRs.
To determine the mechanism through which PPARg acts as a
permissive dimer partner, we performed differential NMR analysis
by adding unlabelled apo-PPARg to 9cRA-bound isotopically
labelled RXRa, with and without addition of the full PPARg
agonist, rosiglitazone (Fig. 1b,d). NMR chemical shift changes in
RXRa are observed on addition of apo-PPARg to the 9cRA-bound
RXRa, consistent with complete formation of a heterodimer
complex. Addition of rosiglitazone causes subtle but signiﬁcant
NMR chemical shift changes in RXRa (for example, S355 and
G429 in the dimer interface) and only minor changes in NMR
resonance linewidths for select residues. Thus, although hetero-
dimerization with and ligand binding to PPARg perturbs the
conformation of RXRa, neither of these events dramatically affects
the ms–ms dynamics of RXRa. This is in contrast to what occurs
with the non-permissive RXR partner, TRb, as detailed below.
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To determine the mechanism through which TRb acts as a non-
permissive RXR heterodimer partner, we performed differential
NMR analysis by adding unlabelled apo-TRb to 9cRA-bound
isotopically labelled RXRa, with and without addition of the TRb
agonist, T3 (Fig. 1b,e). In contrast to PPARg, addition of apo-TRb
exerts a profound effect on the ms–ms conformational dynamics of
9cRA-bound RXRa, where a large number of agonist-bound RXRa
NMR resonances revert to an apo-like NMR proﬁle. NMR
resonances that are destabilized—missing or have broad linewidths
indicating increased ms–ms motion—correspond to RXRa residues
in the ligand-binding pocket (for example, I324, G323, T328,
G329, G341, G343 and S355), helix 11 (for example, G413 and
G429) and other nearby regions such as helix 8 (for example,
G368). Even more striking is that the addition of the TRb agonist,
T3, re-stabilizes these agonist-bound RXRa residues by decreasing
motion on the ms–ms timescale, resulting in a reappearance of
NMR resonances for these regions. Notably, many of the missing
NMR resonances in the apo-TRb/agonist-RXRa heterodimer
correspond to residues in the apo-RXRa homodimer that are
stabilized on binding 9cRA. Our NMR studies indicate that
these residues are not affected by PPARg heterodimerization or
ligand binding to PPARg, but they are signiﬁcantly affected by
TRb heterodimerization and ligand binding to TRb. In total,
these data indicate that the mechanism through which RXRa
is allosterically silenced by TRb but not PPARg, involves
conformational dynamics on the ms–ms timescale.
Structure of the TRbT3/apo-RXRa complex. To further detail
the structural mechanism by which TRb allosterically silences
RXRa, we crystallized apo-RXRa in complex with TRb, T3 and a




























































































































































Figure 1 | NMR reveals a role for conformational dynamics in RXR permissiveness. (a) CV-1 cells co-transfected with PPARg expression plasmid,
RXRa expression plasmid and a PPAR-responsive luciferase reporter. Cells were treated with vehicle, 10 mM 9cRA and/or 10mM rosiglitazone for 24 h.
Magenta and black bars are coloured to match NMR data in d, where ligand content is the same. Luciferase activity is shown normalized to vehicle-treated
cells and was performed in quadruplicate, plotted with the average (±s.e.m) and representative of at least three experiments. (b) CV-1 cells co-transfected
with TRb expression plasmid, RXRa expression plasmid and a TR-responsive luciferase reporter. Cells were treated with vehicle, 100 nM LG100268
(LG268) and/or 1mM T3 for 24 h. Luciferase activity is shown normalized to vehicle-treated cells and was performed in quadruplicate, plotted with the
average (±s.e.m) and representative of at least two experiments. Magenta and black bars are coloured to match NMR data in e, where ligand content is
the same. (c) Structural location of RXR residues mentioned in the NMR analysis. (d) Overlay of 2D [1H,15N]-TROSY-HSQC NMR data for [2H,13C,15N]-
RXRa LBD in the apo form and coloured magenta—with the same bound to 9cRA and coloured black. (e) Overlay of 2D [1H,15N]-TROSY-HSQC NMR data
for [2H,13C,15N]-RXRa LBD bound to 9cRA and heterodimerized to apo-PPARg and coloured magenta—with the same bound to rosiglitazone (Rosi) and
coloured black. (f) Overlay of 2D [1H,15N]-TROSY-HSQC NMR data for [2H,13C,15N]-RXRa LBD bound to 9cRA and heterodimerized to apo-TRb and
coloured magenta—with the same bound to T3 and coloured black.
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was scaled to a resolution of 3.2–3.8 Å and reﬁned to an Rwork/
Rfree of 23.6/28.1% (Table 1). Consistent with other RXR
heterodimer structures, TRb and RXRa interact via the conserved
dimer interface, largely comprised of helix 11 in each monomer,
with additional contacts from helices 8 and 10 (Fig. 2a). TRb
adopts the active conformation when bound to T3, with helix 12
forming one side of the co-activator-binding site, allowing the
docking of the SRC-2 peptide. RXRa displays an inactive
conformation with no bound ligand or co-activator peptide while
helix 12 docks at the AF-2 surface. Although the asymmetric unit
of the TRbT3/apo-RXRa complex is a dimer, the crystal packing
reveals a heterotetramer assembly (Supplementary Fig. 2).
Compared with other NR heterodimer structures, TRbT3/apo-
RXRa displays a more extreme deviation from the C2 (180)
symmetry of the dimer. RXRa helix 7 forms an extensive hydrogen
bond network with TRb helix 9 (Fig. 2a). However, the symmetry-
related RXRa helix 9 and TRb helix 7 are further apart byB3Å,
preventing this sort of interaction. Superposing TRb with an RXRa
subunit in the homodimer structure clearly revealed that the
overall LBD structure is highly conserved (Fig. 2b). However,
superposing these two structures via the RXRa protomer of the
dimer subunits revealed a dramatic shift in the dimer interface
(Fig. 2c). The amino-terminal end of TRb helix 11 is
oriented similarly towards RXRa, while TRb helices 7, 10 and
the carboxyl-terminal part of helix 11 are substantially shifted. As
discussed below, this altered dimer interface induces conforma-
tional changes in RXRa, accounting for its silencing by TRb.
Structural mechanism for silencing of RXR by TR. The
TRbT3/apo-RXRa crystal structure revealed that the structural
basis of RXR silencing is via an allosteric signal emanating
from the middle of the dimer interface. Compared with other
RXR dimers fully occupied by ligands—including the RXRa
homodimer46, and permissive RXR heterodimer complexes with
LXR47 and PPARg48—our structure of the TRbT3/apo-RXRa
heterodimer shows a marked shift in TRb helix 11 (Fig. 3a).
This shift induces a rotation of RXRa helix 11, which is visualized
by comparing our TRbT3/apo-RXRa heterodimer with the
RXRa homodimer (Fig. 3b–d) or with the apo-RXRa tetramer
(Supplementary Fig. 3). In the N terminus of helix 11, TRb T426
is shifted towards RXRa P423 (Fig. 3b), which shows a rotation
away from TRb in the heterodimer structure (Fig. 3c,
Supplementary Fig. 3a). Towards the C terminus of helix 11,
TRb is shifted away from RXRa, leading to a further rotation of
RXRa helix 11 to maintain van der Waals contacts between RXRa
L430 and TRb helix 11 (Fig. 3d, Supplementary Fig. 3b).
Notably, the TRb-directed rotation of RXRa helix 11 in the
TRbT3/apo-RXRa structure induces a corresponding rotation of
the adjacent RXR helix 5, which in turn disrupts the active
conformation of RXRa. In the active conformation of the RXR
homodimer, W305 in helix 5 mediates contacts with the bound
ligand, M454 in helix 12 and L276 in helix 3, which is part of the
AF-2 co-activator-binding surface (Fig. 3e). In contrast, in the
TRbT3/apo-RXRa structure TRb-induced rotation of RXRa
helix 5 in the heterodimer provokes a clash with the active
conformation of helix 12 that pushes both L276 in helix 3 and
M454 in helix 12 away from W305 in helix 5 (Fig. 3f,g).
Importantly, rotation of helix 5 is not observed in the apo-RXRa
homotetramer (Supplementary Fig. 3c), and is thus not a
consequence of the substantial shift in helix 3 that is observed
in both the TRbT3/apo-RXRa and apo-RXRa tetramers, which
is rather determined by the tetramer packing. The electron
density map allows the clear visualization of the main chain
rotation required for interpretation of this data (Supplementary
Fig. 3d,e), and the rotation of helix 5 is signiﬁcant
(Supplementary Fig. 4). Thus in the TRbT3/apo-RXRa structure
the TRb-induced rotation of RXRa helix 11 and helix 5 disables
the active conformation of RXRa.
Structural role of SCA co-evolved amino acids. Work from the
Mangelsdorf and Ranganathan labs10 identiﬁed a network of
co-evolved amino acids that are energetically coupled and
mediate allosteric signalling in RXR heterodimers. A SCA was
used to identify a network of 27 amino acids that comprise an
allosteric signalling network for communication between RXR
and its heterodimer partner. Importantly, an extensive
mutagenesis screen showed that mutation of residues in one
molecule allosterically impacted ligand response (that is,
permissivity) from the partner10, although the structural
mechanism that drives this effect at the atomic level remained
unknown.
Helix 5 lies at the core of the SCA network, and connects the
dimer interface, the ligand-binding pocket and the co-activator-
binding site (Fig. 4a,b). This network includes residues in the
core of RXRa that promote rotation of helix 5 and subsequent
silencing of RXRa, including residues in helix 11 (for example,
L425 and R426), helix 5 (for example, E307 and W305) and helix
3 (for example, L276). RXR R426A and W305A mutants, and the
analogous mutants in a permissive RXR heterodimer partner
afford a dramatic loss-of-function equivalent to helix 12
deletion10. However, while RXR E307A (helix 5) has a modest
effect on function, its analogous mutation in a permissive RXR
heterodimer partner blunts the permissive response with
RXR ligand. The rotation of RXRa W305 observed in the
TRbT3/apo-RXRa structure would directly impact ligand
binding, thereby accounting for the lower afﬁnity of the
TR/RXR heterodimer for RXR ligands34. The importance of
these residues is underscored by the transmission of helix 5
rotation to the co-evolved amino acid residues in helix 3 and helix
4 at the core of the co-activator-binding site (Fig. 4c). Our
Table 1 | Data collection and reﬁnement statistics.
T3-bound TRb/SRC-2/apo-RXRa
Data collection
Space group P 31 2 1
Cell dimensions
a, b, c (Å) 63.25, 63.25 225.81
a, b, g () 90.00, 90.00, 120.00
Resolution (Å) 3.2 (3.31–3.22)*
Rmerge 0.09 (0.7)
I/sI 19.9 (1.46)














Bond lengths (Å) 0.004
Bond angles () 0.65
R.m.s., root mean squared; RXR, retinoid X receptor.
*Data in parenthesis correspond to the highest resolution bin.
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structural data suggests a model where this co-evolved network
controls the rotation of helix 5, thus impacting the dimer
interface, and the ligand- and co-activator-binding sites.
In our TRbT3/apo-RXRa heterodimer structure, RXRa ligand
binding would require RXRa helix 3 to move back into the
agonist conformation, driving RXRa L276 on helix 3 towards
RXRa W305 in helix 5, leading to a reversal of the TRb-induced
rotation of RXRa helix 5. To determine if the conformation of
these RXRa regions are affected by TRb heterodimerzation,
we performed differential HDX mass spectrometry comparing
RXRa in its homodimeric state versus heterodimerized to
TRb. In the presence of T3, 9cRA and co-activator peptide, the
secondary structural elements of TRb-bound RXRa that were
protected from amide exchange centred around P423 in helix 11
and extended to L276 in helix 3, relative to RXRa in the
homodimer (Fig. 4d and Supplementary Table 1). The changes in
HDX support our model where these regions direct allosteric
signalling within the heterodimer resulting in the silencing of
RXR by TR.
To further test the role of helix 5 rotation in connecting the
dimer interface with helix 3, we introduced the RXRa helix 3
mutation L276V, as we hypothesized that the smaller valine
residue at this site (Fig. 3f) would facilitate packing of
helix 3 against the rotated helix 5, even in the presence of RXR
ligand. With the wild-type TRb/RXRa heterodimer, 9cRA
impaired T3-mediated induction of a TR-responsive luciferase
reporter in CV-1 mammalian cells transfected with TRb/RXRa,
shown by a highly signiﬁcant effect of 9cRA in a two-way
analysis of variance (ANOVA, F(1,42)¼ 27; Po0.001).
There was also a trend towards an interaction between the T3
dose and 9cRA terms, suggesting a potential effect of 9cRA on
making T3 less potent (ANOVA, F(6,42)¼ 2; P¼ 0.071).
(Fig. 5a). In contrast, the mutated TRb/RXRa L276V heterodimer
showed a gain-of-function in response to T3 (10- versus
5-fold activation), (ANOVA, WTþT3 versus L276VþT3:
L276V effect F(1,42)¼ 67; Po0.0001) and this mutation
abolished the inhibitory effect of 9cRA on TR activation
(Fig. 5b). These gain-of-function results are consistent with
our model, where the interaction between RXRa W305 in helix 5
and L276 in helix 3 contributes towards the allosteric silencing of
RXR by TR.
Role of helix 11 C terminus in cross-dimer signalling. We also
tested the role of helix 11 in modulating the allosteric signal.
While our studies here point to roles for the N-terminal region of
helix 11 in TRb and RXRa in rotating helix 5, we previously
noted that the C terminus of helix 11 could be differentially
positioned by distinct ligands, thereby controlling the packing of







































Figure 2 | Crystal structure of the TRbT3SRC-2/apo-RXRa LBD complex. (a) Structure of the TR/RXR LBD heterodimer is shown as ribbon with T3 as
space ﬁlled. TR is coloured green, and the bound SRC-2 peptide is coloured blue and only binds to T3TR. RXR is coloured light blue, with the dimer
interface coloured coral and helix 12 coloured purple. There is no bound ligand in RXR, and RXR helix 12 adopts an inactive conformation positioned into the
AF-2 co-activator-binding surface. (b) TR is superimposed on the RXR LBD homodimer (PDB 1MVC), showing conservation of domain structure.
Structures are coloured as in a. (c) Same as b, except dimers are superimposed via the RXR protomer, rather than TR to RXR, illustrating the shift in the TR
dimer interface relative to the other RXR promoter in the RXR homodimer. The magenta circle highlights the only region that superimposes similarly
between TR and RXR, the amino-terminal end of TRb helix 11.
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provides the structural basis for partial agonist activity on NRs, by
titrating the dynamics or stability of helix 12 as it forms the active
conformer22,23. Above we also noted that RXRa E434 can form
hydrogen bonds across the dimer interface with some
heterodimer partners13, right in the plane of the ligands,
suggesting a conduit for structural information from the ligand
to the partner receptor. In total, this suggests that the position of
RXRa helix 11 can be affected by the dimer partner and
modulated by either the RXR ligand or partner ligand. Although

































































RXR / LXR / PPAR
RXR
Figure 3 | TR alters apo-RXR conformation via the helix 11 portion of the dimer interface. (a) Helix 11 of the dimer interface shown as Ca traces for
TRbT3SRC-2/apo-RXRa, coloured green and coral, respectively. The RXR homodimer (PDB 1MVC), RXR/PPARg (PDB 1FM6) and RXR/LXR (PDB 1UHL)
heterodimers were superimposed on the TRbT3SRC-2/apo-RXRa structure using the RXR promoter molecule and are coloured grey. (b–d) The active
conformation RXR homodimer (PDB 1MVC) superimposed on the TRbT3SRC-2/apo-RXRa structure via RXR and coloured as in a, with the RXR
homodimer coloured grey. (b) TR helix 11 (green) induces a shift in the RXR helix 11 (coral) relative to the RXR homodimer (grey). This shift is adjacent to
RXR helix 5. (c) The unique position of TR T426 in helix 11 induces a shift in RXR P423 in helix 11 and a rotation of the RXR helix 11 backbone. (d) The
location of TR A433 in helix 11 away from the dimer interface compared with the equivalent residue in RXR, L430, allows RXR L430 and the RXR helical
backbone to rotate in context of the TRbT3SRC-2/apo-RXRa heterodimer. (e) RXR in the active conformation (PDB 1MVC) with RXR ligand (MBS649)
shown as space ﬁlled and SRC-2 peptide bound to the AF-2 co-activator-binding surface coloured red. RXR W305 in helix 5 mediates contacts with the
ligand, M454 in helix 12 and the co-activator-binding site via L276 in helix 3. Colour is used to help differentiate secondary structural elements and provide
depth for overlapping elements; helix 3 and 4 in cyan, helix 5 in blue, and helix 10/11 and helix 12 in orange. (f) TRbT3SRC-2/apo-RXRa was
superimposed with the active conformation RXR homodimer (PDB 1MVC) and shown as Ca trace. The rotation of helix 5 in TRbT3SRC-2/apo-RXRa
repositions W305 such that it clashes with the active conformation of RXR L276. (g) Same as f, but showing the active conformation of helix 12, and the
clash with the rotated position of W305 in the TRbT3SRC-2/apo-RXRa heterodimer.
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be positioned to potentially interact with TRb S437 in helix 11.
We previously demonstrated a role for this hydrogen bond in
signal integration between RAR/RXR heterodimers21. Mutation
of RXRa E434 to asparagine induced a gain-of-function in
response to T3, both in drosophila SL2 cells that lack endogenous
RXR and TR (Fig. 5c) and in CV-1 monkey cells (Fig. 5d). Thus,
the C terminus of RXRa helix 11 plays a critical role in regulating
the response of the TRb/RXRa heterodimer to T3.
To extend these results, we performed similar experiments with
VDR, which is another heterodimer partner that silences RXR.
Our HDX analysis of the full-length VDR/RXRa heterodimer
with various combinations of ligands, DNA and co-activators
established that vitamin D3 ligand induces stabilization of the
same RXRa regions found here to be affected by TRb, including
helix 3 and helix 11 (ref. 7). We therefore tested a series of RXRa
E434 mutations in complex with VDR, and a mutation of the
corresponding residue in VDR, K395 (Fig. 5e). Although RXR
ligand has no activity on its own, within the context of the VDR/
RXRa heterodimer it is conditionally permissive because it
enhances vitamin D3-induced transactivation. The helix 11
mutations selectively modulate the conditional activation by the
combination of vitamin D3 and RXR agonists, and lead to both
gain- and loss-of-function. Taken together, these data suggest that
similar helix 11-mediated mechanisms control allosteric signal-
ling across the dimer interfaces of TR/RXR and VDR/RXR
heterodimers, and that there are several mechanisms for
heterodimer signal integration.
Ligand signalling in PPARc/RXRa employs SCA network. To
determine if ligand-selective signalling can occur between LBDs in
RXR heterodimers, we took advantage of our extensive structural
and chemical biology efforts with PPARg to compare ligands that
produce different signalling outcomes or graded receptor activa-
tion4,25–27,49. We performed NMR analysis using isotopically
labelled RXRa and unlabelled PPARg to observe conformational
changes in RXRa resulting from ligand binding to PPARg. We
added several PPARg ligands to the apo-PPARg/9cRARXRa
complex (Supplementary Fig. 5); including a full PPARg agonist
(rosiglitazone), a near full agonist (MRL20), a partial agonist
(MRL24) and an antagonist/non-agonist (SR1664). Relative to the
other liganded states, PPARg full agonists rosiglitazone and
MRL20 caused notable NMR chemical shift changes for RXRa
residues at the core of the dimer interface (Fig. 6a,b and
Supplementary Fig. 6), including residues in helix 11 (for
example, S427, I428, G429 and L430) and helix 7 (for example,
T351 and K356). Other more modest NMR resonance shifts are
observed in the RXRa dimer interface, including residues at the N
terminus of helix 10/11 (for example, Q411 and G413).
Importantly, the PPARg full agonist-induced NMR chemical
shift changes for these residues at the core of the dimer interface
were less prominent for the partial agonist and antagonist/non-
agonist, suggesting these RXRa residues are structural sensors for
PPARg ligand activity. Thus, the RXRa dimer interface responds
to PPARg ligands in a manner that tracks with the ligand














































Figure 4 | Co-evolved amino acid network mediates structural allostery between RXR and TR. (a) The TRbT3SRC-2/apo-RXRa structure (green and
coral) superimposed with the active conformation RXR homodimer (PDB 1MVC) via RXR and shown in grey. RXR residues in helix 11 (L425, R426) and helix
5 (W305, E307) are part of a network of co-evolved amino acids identiﬁed using a statistical coupling analysis (SCA). (b) The SCA network amino acids
shown as space ﬁlled on the TRbT3SRC-2/apo-RXRa heterodimer link the dimer interface, ligand-binding pocket and AF-2 co-activator-binding site.
(c) Active conformation RXR homodimer (PDB 1MVC) superimposed with RXR from the TRbT3SRC-2/apo-RXRa heterodimer. Shown are helix 3 and
helix 4 of the AF-2 surface, and W305 in helix 5. The rotation of helix 5 induces an altered conformation of the AF-2 surface via the SCA network amino
acids. (d) Regions in RXR that are protected from HDX on heterodimerizaton with TR.
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A possible mechanism for this allosteric communication
through the RXRa dimer interface involves the C terminus of
PPARg helix 12. We previously demonstrated that PPARg
agonists, but not partial agonists or antagonists, stabilize helix
12 of PPARg4,25–27. In the PPARg/RXRa heterodimer crystal
structure50, RXRa K431 in helix 11 forms a hydrogen bond
with PPARg Y477, the most C-terminal residue in PPARg.
RXRa residues affected differently by the graded PPARg ligands
are structurally close to this region. Thus, the effect of PPARg full
agonists on RXRa residues in the dimer interface are likely
mediated through stabilization of PPARg helix 12 and its
interaction with RXRa.
However, structural perturbations also penetrate into other
regions of RXRa, including the hydrophobic core, ligand-binding
pocket and the AF-2 surface. This includes effects on RXRa core
residues in helix 5 and helix 7 (for example, G304, E307, A311
and L353) (Fig. 6b and Supplementary Fig. 6). One of two
tryptophan residues in the RXRa LBD core (W305 or W282) is
also affected. Helix 5 sits between helix 11 and helix 3 at the nexus
of the ligand-binding pocket and the AF-2 surface. The perturbed
residues provide a direct connection to structural changes in helix
3, the AF-2 surface and the ligand-binding pocket (Fig. 6c and
Supplementary Fig. 6). This includes small, but notable changes
in RXRa helix 3 residue L276, as well as AF-2 surface residues
K284 and S290, which are part of a region that forms electrostatic
interactions with the bound co-activator peptide in the crystal
structures. Thus, RXRa helix 5 is a key part of the LBD core that
transmits PPARg ligand-induced allosteric signals from the dimer
interface to the RXRa ligand-binding pocket and the AF-2
surface.
An additional region of the RXRa LBD core, helix 9, also
mediates PPARg ligand-induced allosteric signalling across
the dimer interface in a similar direction. Helix 9 forms
part of the core that contacts the dimer interface, and stabilizes
the AF-2 surface via interaction with helix 3 and helix 4 residues.
PPARg ligand-induced NMR chemical shift changes in RXRa
helix 11 (for example, Q411 and G413) and helix 9 (for example,
G368), which lie in this region, suggest that helix 9 may
also transmit allosteric information from the dimer interface to
the AF-2 surface. Additional NMR resonances showing
speciﬁc changes in response to PPARg ligands include A457 at
the C terminus of RXRa helix 12 and A327 in the RXRa ligand-
binding pocket.
All together, our NMR data reveal that binding of different
ligands to its heterodimer partner, PPARg, can cause subtle but
signiﬁcant changes in the conformation of RXRa. Using HDX
mass spectrometry, we conﬁrmed that ligand binding to PPARg
imparts structural changes in RXRa (Supplementary Fig. 7 and
Supplementary Table 2). These effects are not only present at the
dimer interface, but also extend through the core of the RXRa
LBD, to the AF-2 surface, helix 12 and the ligand-binding pocket.
As we discuss below, these structural regions involve a network of
co-evolved amino acids in NRs, which are energetically coupled
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Figure 5 | Mutagenesis conﬁrms a structure-function role for co-evolved amino acids. (a,b) CV-1 cells co-transfected with TRb expression plasmid,
(a) RXRa or (b) RXRa L276Vmutant expression plasmid, and a TR-responsive luciferase reporter. Cells were treated with vehicle, or the indicated dose of
T3±1 mM 9cRA for 24 h. (c) Drosophila SL2 cells co-transfected with TRb expression plasmid, RXRa or RXRa E434-mutant expression plasmid, a
TR-responsive luciferase reporter. Cells were treated with vehicle, the RXR agonist LG100268 (LG268; 100nM) and/or 1 mM TR agonist (T3) for 24 h.
(d) CV-1 cells co-transfected with TRb expression plasmid, RXRa or RXRa E434N mutant expression plasmid, and a TR-responsive luciferase reporter. Cells
were treated with vehicle or the indicated dose of T3 overnight. (e) Drosophila SL2 cells co-transfected with VDR expression plasmid, RXRa or RXRa E434-
mutant expression plasmid, and a VDR-responsive luciferase reporter. Cells were treated with vehicle, the RXR agonist LG100268 (LG268; 100nM) and/or
1mM VDR agonist (vitamin D3) for 24 h. Luciferase activity is shown normalized to vehicle-treated cells and was performed in quadruplicate; plotted with
the average±s.e.m and representative of at least three experiments.
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Figure 6 | NMR reveals ligand binding to PPARc affects the conformation of RXR. NMR data are coloured grey for 9cRA-bound RXRa; black for
9cRA-bound RXRa heterodimerized to apo-PPARg or the same bound to the following PPARg ligands: rosiglitazone (magenta), MRL20 (blue), MRL24
(orange) or SR1664 (green); plotted on PPARg/RXRa (PDB 1FM9). (a) NMR data (left) focusing on residues in RXRa helix 7 and helix 10/11 dimer interface
that are perturbed by ligand binding to PPARg, which are plotted onto the PPARg/RXRa crystal structure and coloured according to structural location
(yellow for helix 7; blue for helix 10/11); coloured dark if shown in the NMR data to the left or light if not. (b) NMR data (left) focusing on residues in core of
RXRa that are perturbed by ligand binding to PPARg, which are plotted onto the PPARg/RXRa crystal structure and coloured red; and coloured dark if
shown in the NMR data to the left or light if not. (c) NMR data (left) focusing on residues in RXRa helix 12, the AF-2 surface and the ligand-binding pocket
that are perturbed by ligand binding to PPARg, which are plotted onto the PPARg/RXRa crystal structure and coloured according to structural location
(green for AF-2/helix 12; orange for the ligand-binding pocket); coloured dark if shown in the NMR data to the left or light if not.
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Conservation of allosteric signalling through helix 5. Our data
support a model where TR-induced rotation of RXR helix 5 drives
TR silencing of RXR, and where rotation in the other direction
drives the inhibitory effects of 9cRA on TR via the dimer
interface. We propose that the co-evolved amino acid network
lies at the core of this allosteric mechanism, which is consistent
with our mutagenesis screen showing that these co-evolved amino
acids impact allosteric signalling in RXR heterodimers10. Indeed,
when we calculated NMR chemical shift differences between
PPARg as a monomer versus heterodimerized to RXRa51,
structural perturbations were observed in the regions of the
evolutionarily conserved residues in helix 11 and helix 5 induced
by heterodimerization with RXRa (Fig. 7a).
If an evolutionarily conserved allosteric network directs helix 5
rotation, then it should manifest for other NRs. A comparison of
the structures of the LXR homodimer with the permissive LXR/
RXR heterodimer in the presence of co-activator peptide also
shows that RXR induces a shift in LXR helix 11 that is transmitted
through helix 5, again via the co-evolved amino acid network
(Fig. 7b,c). This shift accommodates a ﬂip of LXR W443 in helix
12 into a position against I295 in helix 5 (Fig. 7c) with additional
van der Waals interactions and greater buried surface area,
thereby stabilizing LXR helix 12 in the agonist conformation.
Thus, RXR-induced rotation of LXR helix 5 is also the
mechanism through which RXR drives co-activator binding to
apo-LXR, a previously unexplained allosteric phenomena in
heterodimer signalling52. This mechanism is also operational for
heterodimers versus monomers of the RAR and the constitutive
androstane receptor (Supplementary Fig. 8), supporting a general
role for helix 5 rotation in allosteric control of RXR heterodimers.
Thus, helix 5 rotation and the evolutionarily conserved
SCA network of amino acid residues provide a structural
conduit for signalling from the dimer partner, through helix 11,
to the ligand-binding pocket and co-regulator-binding surface.
Discussion
While originally conceived as an on/off switch in transcriptional
regulation, it is now clear that NRs contain a number of allosteric
ﬁne-tuning mechanisms that allow a full range of graded signalling
outcomes. NRs can be viewed more generally as dynamic scaffold
proteins, where post-translational modiﬁcations and interaction
with ligands, co-regulators and DNA modify the nature of the
scaffold and the signalling outcomes5,11. A large body of work has
described functional interactions between NR domains and these
interacting molecules, which in sum deﬁne a NR signalling
code2,14. Several studies have investigated various aspects of
permissiveness in RXR heterodimers33,53–55. However, most of the
structural features for allosteric signal integration have remained a
mystery, limited in part by our insufﬁcient structural
understanding of signalling within the individual domains.
Here we used a variety of structural and functional approaches
to show how the dimer partner controls the permissivity, or
activity, of RXRa in the integration of two distinct ligand-
regulated receptors into a single transcriptional response using
residues comprising the SCA network (Fig. 8a). Using NMR and
crystallography, we show that structural differences in RXRa
affected by the different dimer partners, TRb and PPARg, initiate
distinct allosteric signals that suppress or permit modulation of
heterodimer activity through RXRa. These signals are transmitted
through amino acid residues including the co-evolved network
previously identiﬁed by SCA10. Our NMR data reveal that in the
presence of RXR agonist, dimerization with apo-TRb triggers a
considerable change that reinstates an RXRa conformation that
exchanges between two or more conformations on the ms–ms
timescale. When compared with activated RXR homodimer46 and
permissive RXR heterodimer structures, LXR/RXR47 and PPAR/
RXR48, our TRbT3/apo-RXRa crystal structure suggests that
dimerization with the non-permissive partner TRb rotates RXRa

























Figure 7 | Co-evolved amino acid network with other receptors. (a) NMR
chemical shift perturbations in PPARg on heterodimerization with RXRa
mapped onto the structure of the PPARg LBD (PDB 2PRG). (b) LXR
homodimer (PDB 3IPU) coloured grey and superimposed with the LXR
promoter from the LXR/RXR heterodimer (PDB 1UHL) coloured green and
coral, respectively, shows that RXR induces rotation of LXR helix 11. (c) The
RXR-induced shift in LXR helix 11 (PDB 1UHL) induces a rotation of LXR
helix 5 relative to the LXR homodimer (PDB 3IPU), allowing W443 in helix
12 to adopt an alternative conformation with greater van der Waals
contacts and increased buried surface area.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms9013
10 NATURE COMMUNICATIONS | 6:8013 | DOI: 10.1038/ncomms9013 | www.nature.com/naturecommunications
& 2015 Macmillan Publishers Limited. All rights reserved.
induces the apo conformer of RXRa (Fig. 8b). This may account
for the observation that TR lowers the afﬁnity of RXRa for its
ligand34. However, this conformational relay mechanism also
operates in reverse, mediating the intrinsic activity of the
apo-LXR/RXR heterodimer52. Here binding of RXR to LXR
leads to a compensatory rotation of LXR helix 5, which directly
stabilizes LXR helix 12 in the active conformation. Our studies
reveal helix 5 as a central locus for allosteric control between the
dimer interface, helix 12, ligand-binding pocket and AF-2 surface.
The helices that comprise the SCA network act like a set of
interlocking gears to integrate information from the functionally
important sites in the NR LBD.
We identiﬁed a number of distinct routes for signal transduc-
tion through the dimer interface. For example, in our NMR
studies of ligand-selective signalling in PPARg/RXRa, only full
agonists of PPARg, which stabilize helix 12 in the agonist
conformation, induce signiﬁcant alterations in the RXRa dimer
interface adjacent to the C terminus of PPARg helix 12. In this
way, RXRa is able to ‘feel’ the position of the partner helix 12 and
the degree of partner agonist activity. These types of cross-dimer
interactions may also help stabilize helix 12 of the heterodimer
partner in the active conformation, as previously suggested48. A
second set of RXRa regions affected by all of the various PPARg
liganded states include the hydrophobic core, helices 8–10 and
helices 3–4 of the AF-2 surface (Fig. 8c). These regions in general
employ the network of co-evolved residues predicted by SCA. Of
these, PPARg full agonists appear to cause a more prominent
effect, but the speciﬁc role of this structural conduit is not clear. It
could mean that PPARg full agonists may provide additional
stabilization to the RXRa AF-2 surface, or alter the shape of the
AF-2 to give preferences for certain co-activators. Our NMR data
further suggests that this interlocking relay system is also
modulated by the ligand, as one of the two tryptophan residues
in the RXR LBD, W305 in helix 5 or W282 in helix 3, was
differentially sensitive to PPAR ligands. We thus envision that
structural elements in helix 5 of RXR and the dimer partner can
move in a coordinated way with the C-terminal region of the
helix 11 dimer interface to coordinate both receptor- and ligand-
speciﬁc signals into an integrated transcriptional response with
the co-evolved amino acids playing a primary role.
We identiﬁed the C terminus of helix 11, adjacent to the bound
ligands, as also contributing to heterodimer signalling. Within
each monomer, there are two known mechanisms through which
different ligands can produce a range of signalling outcomes from
full agonist to antagonist. One is by direct modulation of helix 12,
where the physical contact between ligand and helix 12
determines the percentage of time the active conformation of
helix 12 is stabilized, docked across helix 3 and helix 11 to form
the AF-2 surface. A second mechanism—indirect modulation—
occurs when the ligand can position helix 11 so as to provide
suboptimal van der Waals packing with helix 12, and thus
indirectly control its stability in the agonist conformation21–24.
Our data suggest an extension of this model where the position of
helix 11 is also controlled by the heterodimer partner helix 11.
Our mutagenesis data further suggests that the C terminus of
helix 11 is also positioned by the type of dimer partner, in
addition to the speciﬁc ligand, contributing to permissive versus
non-permissive heterodimer signal integration.
Methods
Protein expression, puriﬁcation and ligands. Human RXRa LBD (amino acids
223–462), human TRb LBD (residues 202–461) and human PPARg LBD (residues
203–477; isoform 1 numbering) were cloned into a pET vector with a ligation-
independent cloning site as TEV-cleavable hexahistidine-tagged (His-tag) fusion
proteins. RXRa LBD was induced in BL21(DE3) cells, and puriﬁed with immo-
bilized nickel afﬁnity chromatography. The eluted protein was mixed with a 1:30
ratio (by mg weight) of His-tag TEV protease and dialysed overnight in 20mM
Tris pH 8, 50mM NaCl, 50mM b-mercaptoethanol and 10% glycerol. The protein
solution was again puriﬁed using immobilized nickel afﬁnity chromatography to
remove uncut protein, the cut His-tag and the TEV protease. The ﬂow through was
diluted 2 in H2O and subjected to gel ﬁltration in buffer consisting of 20mM
Tris 8.0, 50mM NaCl, 10% glycerol and 5mM b-mercaptoethanol. TRb LBD was
induced in BL21(DE3)Rosetta cells, and puriﬁed with immobilized nickel afﬁnity
chromatography (Qiagen) in a manner identical to that of RXRa. For crystal-
lography, puriﬁed TRb LBD that had not been subjected to TEV proteolysis was
incubated with puriﬁed RXR lacking a His-tag (at a ratio of 2:1 RXR to TR). The





































Figure 8 | Summary of structural studies and allostery in RXR
heterodimers. (a) The SCA network residues plotted on RXR using the
PPARg/RXRa heterodimer structure as a model (PDB 1FM6). (b) Schematic
diagram summarizing our TRbT3SRC-2/apo-RXRa crystal structure
showing how TR structurally silences RXR. The signal that emanates
from TR (i) induces a shift in RXR helix 11 (ii), leading to a rotation of helix 5
(iii) resulting in structural arrangements that cause RXR helix 12 to adopt
an inactive conformation (iv). (c) Summary of residues affected in the
NMR analysis of ligand-selective signalling in PPARg/RXRa, plotted on
PDB 1FM6. Helix numbers are indicated for elements of interest. Arrows
indicate the ﬂow of the allosteric signal.
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buffers and gradients as described above and then the TR LBD His-tag was
removed by proteolysis with TEV protease overnight while the complex was being
dialysed to 20mM Tris 8.0, 150mM NaCl, 5mM BME and 10% glycerol. PPARg
LBD was expressed and puriﬁed using similar methods, and ﬁnal NMR sample
conditions contained 20mM KPO4 (pH 7.4) and 50mM KCl56. Ligands were
purchased from commercial sources, or in the case of MRL20, MRL24 and SR1664
were synthesized27,57.
NMR spectroscopy and analysis. NMR data were collected at 298K on a
700MHz Bruker NMR instrument equipped with a conventional TXI triple reso-
nance probe and on a 800-MHz Varian NMR instrument equipped with a cryo-
genically cooled triple resonance probe. Ligands that were added to proteins were
dissolved in DMSO-d6. NMR experiments were performed using pulse sequences
and standard experimental parameters provided with Bruker Topspin 3.0. RXRa
LBD chemical shift assignments37 were validated and/or transferred to various
complexed states using standard 2D and 3D NMR TROSY-based methods, including
HSQC, HNCO, HNCA, HN(CO)CA and HN(CA)CB and 15N-NOESY-HSQC
experiments. Data were processed using Bruker Topspin 3.0 or NMRPipe58 and
analysed with NMRViewJ59. NMR chemical shift perturbations (DdCSP) for PPARg
LBD in the monomer form and heterodimerized to RXRa LBD were calculated
from published values51 as follows: DdCSP¼ |DdHN|þ (0.154 |DdN|)þ
(0.341 |DdC0|); with DdHN, DdN and DdC0 as the backbone 1HN, 15N and 13C0
(carbonyl) NMR chemical shift differences between monomer and heterodimer,
respectively, and mapped onto the PPARg LBD crystal structure (PDB 2PRG).
Crystallization, structure determination and reﬁnement. The TRbT3SRC-2/
apo-RXRa complex was formed by mixing a threefold molar excess of T3 (Sigma)
and SRC-2 peptide (HKILHRLL). Crystal trials were initially conducted using
commercially available sparse matrix screens, from which microcrystals were iden-
tiﬁed and subsequently streak seeded to produce a high resolution diffracting crystal.
The well solution consisted of 20% PEG 3350, 100mM Tris pH 8.0, 0.1M ammo-
nium acetate and 1mM 11-Methoxy-3,7,11-trimethyl-2E,4E-dodecadienoic acid. The
crystal was ﬂash cooled with liquid nitrogen after brieﬂy immersing in paratone-n as
a cryo-protectant. Data was collected at SSRL beamline 11-1 at 100K. The structure
was solved with molecular replacement using Phaser60 using search models for TR
(PDB 3GWS) and RXR (PDB 1G5Y). Initially scaled at 3.5Å, the model was reﬁned
using PHENIX61 to an Rfree of 33%. The data set was anisotropic and was therefore
rescaled to 3.2Å and truncated to 3.2 3.8Å based on a 1.5 signal-to-noise (s) cut-
off using the UCLA Diffraction Anisotropy Server62. This allowed the reﬁnement to
lower the Rwork/Rfree to 23.6/28.1%. The reported Rmerge for our structure is from
the pre-truncated data set and was not used to determine the resolution cut-off.
Instead, an anisotropic cut-off of 1.5s was used based on recommendations of
Brunger et al.63,64 to avoid discarding reﬂections when working with low resolution
structures and with modern reﬁnement practices that can accommodate lower signal
reﬂections. Thus, the very good Rfree and geometry statistics for this resolution likely
reﬂect the use of higher resolution structures for molecular replacement. The TLSMD
server was used to identify optimal TLS groups65. The model was rebuilt using
COOT66. Structural ﬁgures were generated with CCP4MG67.
HDX mass spectrometry. HDX was performed using a fully automated in-house
system49,68 with some modiﬁcations. Brieﬂy, protein samples are incubated with
D2O-containing buffer at 4 C for 10, 30, 60, 900 and 3,600 s. Following on-
exchange, forward or back exchange was minimized and the protein was denatured
by dilution with 25ml of quench solution (0.1% v/v triﬂuoroacetic acid/TFA in 3M
urea). Samples were then passed through an immobilized pepsin column (prepared
in-house) at 50ml min 1 (0.1% v/v TFA, 15 C) and the resulting peptides were
trapped on a C8 trap column (Hypersil Gold, Thermo Fisher). The bound peptides
were then gradient eluted (5–50% CH3CN w/v and 0.3% w/v formic acid) across a
2 50-mm C18 HPLC column (Hypersil Gold) for 5min at 4 C. The eluted
peptides were then subjected to electrospray ionization directly coupled to a high
resolution Orbitrap mass spectrometer; Exactive for TR/RXR or QExactive for
PPARg/RXR (Thermo Fisher Scientiﬁc). For TR/RXR measurements, 4 ml of 10 mM
protein was diluted to 20 ml of D2O buffer. Following the prescribed on-exchange
interval, the reaction was quenched with a cold 3-M urea solution containing 1%
TFA and 50mM TCEP. For PPARg/RXR measurements, 10 mM of HIS-PPARg
LBD protein (20mM KPO4 pH 7.4, 50mM KCl) in complex with 10 mM FLAG-
RXR LBD (20mM KPO4 pH 7.4, 50mM KCl) was preincubated with 1:2 molar
excess of compound. About 5 ml of protein solution was mixed with 20 ml of D2O-
containing buffer (20mM KPO4 pH 7.4, 50mM KCl) to initiate on-exchange.
Following on-exchange, forward or back exchange was minimized and the protein
was denatured by dilution with 25 ml of quench solution (0.1% v/v TFA in 3M
urea). HDX values are the average of three individual on-exchange experiments
acquired in a random order. HDX data analysis was performed with ‘HDX
Desktop’ for TR/RXR samples and ‘HDX Workbench’ for PPARg/RXR69,70. Each
HDX experiment was carried out in triplicate and the intensity-weighted average
m/z value (centroid) of each peptide isotopic envelope was calculated. Data-
dependent tandem mass spectroscopy was performed in the absence of exposure to
deuterium for peptide identiﬁcation in a separate experiment using a 60-min
gradient. Peptides with a Mascot score of Z20 were included in the peptide sets
used for HDX.
Cell culture and luciferase co-transfection assays. CV-1 cells (ATCC) were
maintained in DMEM (Invitrogen) with 10% FBS charcoal/dextran –treated
(Hyclone). Cells were transfected using Fugene HD (Roche) with a DR-4 luciferase
reporter with expression plasmids for RXRa and TRb. After 6 h, cells were pas-
saged and transferred into 384-well plates. Ligands were added the next day and
allowed to incubate overnight before processing for luciferase activity. An equal
volume of Britelite (PerkinElmer) was dispensed and the luminescence was mea-
sured on an Analyst GT plate reader (PerkinElmer). Drosophila SL2 cells (ATCC)
were maintained in Schneider Drosophila Medium (Gibco) containing 5%
dextran–charcoal-stripped FBS and transfected at a density of 6,500 cells per well in
96-well plates by calcium phosphate co-precipitation. Co-transfection experiments
included 50 ng of reporter plasmid, 20 ng of b-galactosidase expression plasmid,
15 ng of each receptor expression plasmid and PGEM carrier DNA to give a total of
150 ng of DNA per well of a 96-well plate. Cells were transfected for 8 h and were
treated for 18 h before harvesting and determination of luciferase and b-galacto-
sidase activity. Luciferase data were normalized to the internal b-galactosidase
control and represent the mean of triplicate assays plus s.e. Fold induction values
were calculated as ligand-induced relative luciferase units/control relative luciferase
units and propagated errors were calculated. Experiments used human full-length
RXRa, TRb, PPARg and VDR expression plasmids with the appropriate luciferase
reporter plasmid10, including TREx2-luc (TR-luc), PPREx3-luc (PPAR-luc) or
ADH-mSppx3-luc (VDR-luc). RXR mutant expression plasmids were generated
using the Stratagene QuikChange Site-Directed Mutagenesis kit and veriﬁed by
DNA sequencing. Statistical analyses were performed with Graphpad Prism.
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